Duratia

Duratia (Dapoxetine Hydrochloride) is a prescription medication specifically formulated for the management of premature ejaculation (PE) in adult men. As a selective serotonin reuptake inhibitor (SSRI) with a short half-life, it represents a significant advancement in on-demand treatment for this common sexual health condition. Developed through rigorous clinical research, Duratia works by increasing serotonin activity in the central nervous system, thereby improving ejaculatory control. This medication provides a targeted therapeutic approach that allows for flexible dosing in anticipation of sexual activity, offering both efficacy and convenience for appropriate patients under medical supervision.

Features

• Active ingredient: Dapoxetine Hydrochloride 30mg or 60mg
• Pharmaceutical form: Film-coated tablets
• Rapid onset of action: Typically within 1-2 hours
• Short elimination half-life: Approximately 1.5-2 hours
• High protein binding: Approximately 99%
• Extensive hepatic metabolism primarily via CYP enzymes
• Renal excretion as metabolites

Benefits

• Significantly increases intravaginal ejaculatory latency time (IELT)
• Improves perceived control over ejaculation
• Enhances sexual satisfaction for both partners
• Reduces personal distress related to premature ejaculation
• Provides on-demand dosing flexibility without need for continuous administration
• Demonstrated safety profile in clinical trials involving thousands of patients

Common use

Duratia is indicated for the treatment of premature ejaculation (PE) in men aged 18-64 years. Premature ejaculation is defined as persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it, which causes marked distress or interpersonal difficulty. The medication is intended for use in men who have established, stable sexual relationships and who meet diagnostic criteria for lifelong or acquired premature ejaculation. Clinical studies have demonstrated efficacy across various patient populations, though individual response may vary based on physiological factors and adherence to dosing guidelines.

Dosage and direction

The recommended starting dose is 30mg taken approximately 1-3 hours before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 60mg. The tablet should be swallowed whole with at least one full glass of water. Duratia may be taken with or without food, though high-fat meals may delay absorption. The medication should not be taken more than once every 24 hours. Patients should be advised that sexual stimulation is required for Duratia to be effective. Dose adjustment is recommended for patients with renal or hepatic impairment, and concurrent use with potent CYP3A4 inhibitors is contraindicated.

Precautions

Patients should be screened for history of manic episodes or bipolar disorder before initiation. Caution is advised in patients with underlying psychiatric conditions. Orthostatic hypotension may occur; patients should be advised to rise slowly from sitting or lying positions. Use with caution in patients with conditions that might predispose to hypotension (dehydration, antihypertensive medications). Patients should avoid alcohol consumption while taking Duratia due to increased risk of adverse events including dizziness, syncope, and hypotension. Regular follow-up with healthcare provider is recommended to assess continued need and monitor for adverse effects.

Contraindications

Duratia is contraindicated in patients with known hypersensitivity to dapoxetine or any excipients in the formulation. Concurrent administration with monoamine oxidase inhibitors (MAOIs), thioridazine, or potent CYP3A4 inhibitors (including ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir) is contraindicated. Patients with significant hepatic impairment (Child-Pugh Class C) should not use Duratia. The medication is contraindicated in patients with history of mania or severe depression, and in those with established cardiovascular conditions where sexual activity is not advised.

Possible side effects

Common adverse reactions (≥1%) include nausea (11.0%), dizziness (5.8%), headache (5.5%), diarrhea (3.9%), insomnia (3.1%), and fatigue (2.1%). Less frequently reported effects include vomiting, abdominal pain, flushing, increased blood pressure, tachycardia, anxiety, tremors, and blurred vision. Syncope has been reported in approximately 0.1% of patients in clinical trials. Most adverse events are mild to moderate in severity and tend to decrease in frequency with continued use. Patients should be advised to report any persistent or concerning symptoms to their healthcare provider.

Drug interaction

Duratia is primarily metabolized by CYP3A4, CYP2D6, and flavin-containing monooxygenase 1 (FMO1). Concomitant use with CYP3A4 inhibitors may significantly increase dapoxetine exposure. Concurrent administration with SSRIs, SNRIs, or tricyclic antidepressants may increase risk of serotonin syndrome. Potent CYP2D6 inhibitors may increase dapoxetine exposure approximately 2-fold. Use with alcohol increases the risk of adverse events including dizziness, syncope, and hypotension. Concomitant use with medications affecting serotonin neurotransmission requires careful monitoring. Herbal supplements containing St. John’s Wort should be avoided due to potential interactions.

Missed dose

As Duratia is taken on an as-needed basis rather than on a scheduled regimen, the concept of a “missed dose” does not apply in the conventional sense. Patients should take one tablet approximately 1-3 hours before anticipated sexual activity. If sexual activity does not occur after taking Duratia, no additional dose should be taken within the same 24-hour period. Patients should not take more than one dose in any 24-hour period regardless of circumstances.

Overdose

In case of suspected overdose, immediate medical attention should be sought. Symptoms may include serotonin syndrome manifestations (agitation, confusion, diaphoresis, tachycardia, hypertension, hyperthermia, muscle rigidity), dizziness, nausea, vomiting, and syncope. There is no specific antidote for dapoxetine overdose. Treatment should consist of general supportive measures including monitoring of vital signs and symptomatic treatment. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may be administered if the patient presents within 1-2 hours of ingestion.

Storage

Store at room temperature between 15-30°C (59-86°F). Protect from light and moisture. Keep in original packaging until time of use. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication that has expired or is no longer needed through medication take-back programs or according to local regulations.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Duratia is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Patients should consult with their physician for proper diagnosis and treatment recommendations. Individual results may vary, and not all patients will experience the same benefits or side effects. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use or misuse of this information.

Reviews

Clinical trials involving over 6,000 patients demonstrated that Duratia significantly improved IELT and patient-reported outcomes measures compared to placebo. In phase III studies, mean IELT increased from approximately 0.9 minutes at baseline to 3.1-3.2 minutes with Duratia 30mg and 3.4-3.5 minutes with Duratia 60mg. Patient Global Impression of Change (PGI-C) scores showed 70-80% of patients reported much-improved or very-much-improved control over ejaculation. Partner satisfaction scores similarly improved significantly compared to placebo. Real-world evidence studies have corroborated these findings, with sustained efficacy reported over 24 months of treatment in open-label extension studies.